Business
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale”, a leading cancer centre in Europe The NEO-CYT Study will evaluate MDNA11 as a neoadjuvant immunotherapy in earlier-stage melanoma patients whose immune systems are more amenable to immunotherapy and may be more likely to benefit from MDNA11 treatment Based on
About this update from Medicenna Therapeutics Corp.
[{"type":"image","alt":"Medicenna Therapeutics Corp.","displaySize":"","headline":null,"caption":"Medicenna Therapeutics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/33fcbf6dc1c4c8dceac4cdb8f9da49c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iKkUSgUQdlNQdX43zhjRLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/33fcbf6dc1c4c8dceac4cdb8f9da49c2","width":300,"height":38}},"lazy":false},{"type":"text","content":"NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale”, a leading cancer centre in Europe","length":273,"tagName":"p"},{"type":"text","content":"The NEO-CYT Study will evaluate MDNA11 as a neoadjuvant immunotherapy in earlier-stage melanoma patients whose immune systems are more amenable to immunotherapy and may be more likely to benefit from MDNA11 treatment","length":216,"tagName":"p"},{"type":"text","content":"Based on deep and durable responses reported to date in the ABILITY-1 study treating patients with end-stage advanced metastatic and non-resectable tumors, MDNA11 is believed to have the potential to profoundly reduce the risk of cancer returning after initial surgery ","length":268,"tagName":"p"},{"type":"text","content":"MDNA11 will be evaluated in combination with the checkpoint inhibitors nivolumab (anti-PD1) alone or with ipilimumab (anti-CTLA4), with Major Pathologic Response (MPR) as a primary endpoint, which is considered predictive of long-term survival outcomes","length":252,"tagName":"p"},{"type":"text","content":"Under the terms of the clinical trial collaboration, the Fondazione Melanoma Onlus is the Sponsor and Medicenna will supply the study medications ","length":145,"tagName":"p"},{"type":"text","content":"Medicenna’s runway remains unchanged with cash & equivalents expected to last into at least the middle of calendar 2026","length":123,"tagName":"p"},{"type":"text","content":"TORONTO and HOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines f...